Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?

Hemophilia defines a condition that predisposes to bleeding, and is caused by deficiency or defect in certain clotting factors, the most common being Hemophilia A [factor VIII (FVIII) deficiency] and Hemophilia B [factor IX (FIX) deficiency]. The current treatment for patients with Hemophilia, so that patients are less likely to bleed, entails replacement of the missing factor(s). This was achieved historically using factor concentrates derived from human donor blood plasma, and later using recombinant technology.